Tipranavir: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Tipranavir}} | ||
'''''For patient information, click <u>[[ | '''''For patient information, click <u>[[Tipranavir (patient information)|here]]</u>'''''. | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
| Line 29: | Line 29: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
protease inhibitor of HIV-1 | protease inhibitor of HIV-1 | ||
==References== | ==References== | ||
Revision as of 13:13, 9 January 2014
For patient information, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overview
Category
US Brand Names
Aptivus®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
protease inhibitor of HIV-1